EXAS241220C70000
- 0.37
- -0.08-17.78%
Exact Sciences Newsroom
Exact Sciences and Lil Jon Partner on "Get Low #2" Campaign to Encourage Colon Cancer Screening
Trending Stocks This Week as Holiday Season Begins With Thanksgiving Break
US MOVERS&SHAKERS Nov 25-Nov 29, 2024
Top Gap Ups and Downs on Tuesday: LLY, ZM, BBY and More
What 19 Analyst Ratings Have To Say About Exact Sciences
Exact Sciences Is Maintained at Buy by TD Cowen
Express News | TD Cowen Maintains Buy on Exact Sciences, Raises Price Target to $86
Exact Sciences Is Maintained at Buy by BTIG
Why Is Exact Sciences Stock Trading Higher On Monday?
Exact Sciences Analyst Ratings
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
BTIG Raises Price Target on Exact Sciences to $75 From $65, Maintains Buy Rating
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $67 to $86
Exact Sciences Shares Are Trading Higher. The Company Announced It Will Present 10 Abstracts at SABCS.
S&P 500 Futures Climb In Premarket Trading; Woodward, Exact Sciences Lead
Piper Sandler Releases a Buy Rating on Exact Sciences (EXAS)
Daniel Brennan Upgrades Exact Sciences to Buy After Cologuard Plus Price Increase
Exact Sciences' Revenue Boost: Impact of CMS Pricing Decision on Cologuard Plus
Exact Sciences to Participate in December Investor Conferences
Express News | Exact Sciences To Present 10 Abstracts Demonstrating Breadth Of Its Precision Oncology Portfolio At SABCS